Jekunen et al: Strategy of sensitizing tumor cells with adenovirus-p53 transfection Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. (1994). “p53 status and the efficacy of cancer therapy in vivo.” Science 266(5186): 807-10. Lowe SW, Ruley HE, Jacks T, and Housman DE. (1993). “p53mediated apoptosis modulates the cytotoxicity of anticancer agents.” Cell 74: 957-967. McPake CR, Shetty S, Kitchingman GR, Harris LC.. (1999). “Wild-Type p53 Induction Mediated by Replication-deficient Adenoviral Vectors.” Cancer Res 59(17): 4247-907. Miyake H, Hara I, Gohji K, Yamanaka K, Arakawa S, Kamidono S. (1998). “Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer.” Anticancer Res 18(4C): 3087-92. Miyake H, Hara I, Hara S, Arakawa S, Kamidono S. (2000). “Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model.” Urology 56(2): 332-6. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA (1996). “Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirus-mediated p53 transfer.” J Thorac Cardiovasc Surg 112: 1372-1376. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW. (1997). “Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.” Cancer Res 57(19): 4285-300. Oren, M. (1992). “p53: the ultimate tumor suppressor gene?” Faseb J 6(13): 3169-76. Osaki S, Nakanishi Y, Takayama K, Pei XH, Ueno H, Hara N. (2000). “Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells.” Cancer Gene Ther 7(2): 300-7. Parker LP, Wolf JK, Price JE. (2000). “Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.” Ann Clin Lab Sci 30(4): 395-405. Peller, S. (1998). “Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response.” Semin. Cancer Biol. 8: 379-387. Perdomo JA, Naomoto Y, Haisa M, Fujiwara T, Hamada M, Yasuoka Y, Tanaka N. (1998). “In vivo influence of p53 status on proliferation and chemoradiosensitivity in nonsmall-cell lung cancer.” J Cancer Res Clin Oncol 124(1): 10-8. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. (1997). “A model for p53-induced apoptosis.” Nature 389: 300. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G, Zunino F. (1996). “A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.” Cancer Res 56(4): 689-93. Roth, J. A. (1996). “Modification of tumor-suppressor-gene expression and induction of apoptosis in non-small-cell lung cancer (NSCLC) with an adenovirus vector expressing wildtype p53 and cisplatin.” Hum Gene Ther 7: 1013-1030. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, Shin DM, Walsh GL, Dolormente
MM, Han CI, Martin FD, Yen N, Xu K, Stephens LC, McDonnell TJ, Mukhopadhyay T, Cai D. (1996). “Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.” Nature Medicine 2(9): 985991. Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA 3rd, Miller DS, Mathis JM. (1995). “Adenovirus-based p53 gene therapy in ovarian cancer.” Gynecol Oncol 59(2): 171-8. Schornagel JH, Verweij J, de Mulder PH, Cognetti F, Vermorken JB, Cappelaere P, Armand JP, Wildiers J, de Graeff A, Clavel M, et al, (1995). “Randomized phase III trial of adatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: A European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study.” JCO 13: 1649-1655. Schuler M, Herrmann R, De Greve JL, Stewart AK, Gatzemeier U, Stewart DJ et al (2001). “Adenovirus-Mediated WildType p53 Gene Transfer in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results of a Multicenter Phase II Study.” J Clin Oncol 19(6): 1750-1758. Selter, H. and M. Montenarh (1994). “The emerging picture of p53.” Int J Biochem 26: 154-154. Shahin MS, Hughes JH, Sood AK, Buller RE. (2000). “The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.” Cancer 89(9): 2006-17. Sherr, C. J. (1994). “G1 phase progression: cycling on cue.” Cell 79: 55-62. Stal, O. (1995). “p53 expression and the result of adjuvant therapy of breast cancer.” Acta Oncologica 34: 767-770. Sugrue MM, Shin DY, Lee SW, Aaronson SA. (1997). “Wildtype p53 triggers a rapid senescence program in human tumor cells lacking functional p53.” Proc Natl Acad Sci U S A 94(18): 9648-53. Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, Connors DG, El-Naggar AK, Fossella F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merritt JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam JB Jr, Richli WR, Savin M, Waugh MK, et al, (1999). “Adenovirus mediated p53 gene tranfer in advanced non-small-cell lung cancer.” J Natl Cancer Inst 91: 763-771. Trepel M, Groscurth P, Malipiero U, Gulbins E, Dichgans J, Weller M. (1998). “Chemosensitivity of human malignant glioma: modulation by p53 gene transfer.” J Neurooncol 39(1): 19-32. Wolf JK, Mills GB, Bazzet L, Bast RC Jr, Roth JA, Gershenson DM. (1999). “Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status.” Gynecol Oncol 75(2): 261-6. von Gruenigen VE, Santoso JT, Coleman RL, Muller CY, Miller DS, Mathis JM. (1998). “In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.” Gynecol Oncol 69(3): 197-204. Xu GW, Sun ZT, Forrester K, Wang XW, Coursen J, Harris CC. (1996). “Tissue-specific growth suppression and chemosensitivity promotion in human hepatocellular carcinoma cells by retroviral-mediated transfer of the wildtype p53 gene.” Hepatology 24(5): 1264-8. Yang B, Eshleman JR, Berger NA, Markowitz SD. (1996). “Wild-type p53 protein potentiates cytotoxicity of
34